NCT05764941 2023-03-27
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Unknown
Clinical Trials
6 trialsNCT05561686 2022-09-30
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Hunan Cancer Hospital
Unknown
NCT05030519 2022-03-02
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Zhejiang Cancer Hospital
Unknown
NCT04899128 2021-05-24
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT04683445 2020-12-24
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT04609540 2020-12-16
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Shandong Cancer Hospital and Institute
Unknown